Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Rating) shares saw unusually-high trading volume on Friday . Approximately 2,506 shares were traded during mid-day trading, a decline of 98% from the previous session's volume of 126,123 shares.The stock last traded at $66.60 and had previously closed at $65.69.

Analysts Set New Price Targets

Several equities research analysts have commented on ESTA shares. Stephens lowered their price target on shares of Establishment Labs from $90.00 to $87.00 and set an "overweight" rating on the stock in a report on Wednesday, December 28th. BTIG Research upped their price target on shares of Establishment Labs from $90.00 to $100.00 and gave the company a "buy" rating in a report on Friday, October 7th. Finally, Mizuho started coverage on shares of Establishment Labs in a report on Wednesday, October 12th. They issued a "buy" rating and a $70.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Establishment Labs presently has an average rating of "Moderate Buy" and a consensus price target of $97.00.

Establishment Labs Stock Performance

The firm's 50 day moving average price is $65.34 and its 200-day moving average price is $60.84. The company has a debt-to-equity ratio of 97.56, a quick ratio of 3.29 and a current ratio of 4.27. The firm has a market capitalization of $1.67 billion, a PE ratio of -22.10 and a beta of 1.06.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. BNP Paribas Arbitrage SA raised its position in shares of Establishment Labs by 3,244.4% during the 1st quarter. BNP Paribas Arbitrage SA now owns 602 shares of the company's stock worth $41,000 after purchasing an additional 584 shares during the last quarter. Lazard Asset Management LLC raised its position in shares of Establishment Labs by 104.5% during the 1st quarter. Lazard Asset Management LLC now owns 963 shares of the company's stock worth $64,000 after purchasing an additional 492 shares during the last quarter. BNP Paribas Arbitrage SNC raised its holdings in Establishment Labs by 100.6% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 1,689 shares of the company's stock valued at $92,000 after acquiring an additional 847 shares during the last quarter. Bank of America Corp DE raised its holdings in Establishment Labs by 38.4% in the 1st quarter. Bank of America Corp DE now owns 2,227 shares of the company's stock valued at $150,000 after acquiring an additional 618 shares during the last quarter. Finally, Twin Lakes Capital Management LLC acquired a new stake in Establishment Labs in the 3rd quarter valued at about $163,000. Institutional investors and hedge funds own 75.26% of the company's stock.

Establishment Labs Company Profile

(Get Rating)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.

Further Reading

• Get a free copy of the StockNews.com research report on Establishment Labs (ESTA)
• MarketBeat Week in Review – 1/16 – 1/20
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.